Vol. 6, Issue 1, Part B (2024)

This comprehensive review explores recent advancements in diabetes management, encompassing technological innovations and pharmacological developments. Key findings include the introduction of smart insoles and boots for diabetic foot ulcers, promising non-pharmacological approaches like plant-based α-amylase inhibitors, and the emergence of top choices such as Semaglutide, dulaglutide, and liraglutide among glucagon-like peptide-1 receptor agonists. Innovative drug delivery systems, exemplified by the LG/TD-NF nano formulation, offer potential benefits over traditional injections. Recent guidelines emphasize early detection and personalized treatment plans, with a focus on SGLT2 inhibitors and GLP-1 receptor agonists for type 2 diabetes. Genetic studies have identified unique mutations like m.A5826G linked to type 2 diabetes, providing insights into potential early detection and treatment targets. Overall, these advancements offer hope for improved diabetes management and underscore the importance of continued research and clinical trials to validate their effectiveness and integrate them into standard practice, ultimately enhancing patient outcomes.